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Developing stable Chinese hamster ovary (CHO) cell lines for biotherapeutics is an irreversible process and 
therefore, key quality attributes, such as sequence variants, must be closely monitored during cell line 
development (CLD) to avoid delay in the developmental timeline, and more importantly, to assure product safety 
and efficacy. Sequence variants, defined as unintended amino acid substitution in recombinant protein primary 
structure, result from alteration at either the DNA or the protein level. Here we report the application of 
transcriptome sequencing (RNAseq) in an IgG1 monoclonal antibody (mAb) CLD campaign to detect, identify 
and eliminate cell lines containing low-level point mutations in recombinant coding sequence. Among the top 
eleven mAb producers chosen from transfectant, clone or subclone stages, three of the cell lines contained 
either missense or nonsense point mutations at a low-level of less than 2%. Subsequent LC/MS/MS 
characterization detected ~3% sequence variants with an amino acid change from Ser to Leu at residue 117 in 
the heavy chain of transfectants 11 and 27. This substitution is consistent with the RNAseq finding of a C/T 
mutation located at 407 base pair (TCA→TTA) in the heavy chain coding sequence. Here, for the first time, we 
demonstrate that RNAseq is a rapid and highly sensitive method to identify low-level genetic mutation de novo 
corresponding to the amino acid substitution that elicits sequence variant(s). Its implementation in CLD 
constitutes an early and effective step in identifying desired CHO expression cell lines. As a continued effort to   
expedite the turnaround time and lower the developmental cost, we are further exploring other NGS approaches 
including cDNA (GOI) deep sequencing via Miseq and the preliminary data indicate a comparable sensitivity in 
detecting low-level point mutations. 
 
